Relative Vaccine Effectiveness of Adjuvanted Quadrivalent Inactivated Influenza Vaccine vs High-Dose Quadrivalent Inactivated Influenza Vaccine Among Adults ≥65 Years for the 2023-24 and 2024-25 Seasons
Status: Recruiting
Location: See location...
Intervention Type: Biological
Study Type: Observational
SUMMARY
This study will evaluate the relative vaccine effectiveness of quadrivalent adjuvanted inactivated influenza vaccine (aIIV4) versus quadrivalent high-dose inactivated influenza vaccine (HD-IIV4) in preventing polymerase chain reaction (PCR)-confirmed influenza and influenza-related outcomes in adults ≥65 years of age during the 2023/24 and 2024/25 influenza seasons. The study is an observational study conducted at Kaiser Permanente Northern California (KPNC), an integrated health care system in the United States.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 65
Healthy Volunteers: t
View:
• Age ≥65 years at the time of influenza vaccination
• KPNC member at the time of vaccination
• Receive either aIIV4 or HD-IIV4 at a KPNC facility during the 2023/24 and/or 2024/25 influenza seasons
Locations
United States
California
Kaiser Permanente Northern California (entire region)
RECRUITING
Oakland
Contact Information
Primary
Amber H. Hyman, PhD, MPH
Amber.Hyman@kp.org
510-267-7571
Time Frame
Start Date: 2023-08-17
Estimated Completion Date: 2026-05
Participants
Target number of participants: 960000
Treatments
Fluad Recipients
Kaiser Permanente Northern California members aged ≥65 years who receive Adjuvanted Quadrivalent Inactivated Influenza Vaccine (aIIV4)
Fluzone High-Dose Recipients
Kaiser Permanente Northern California members aged ≥65 years who receive High-Dose Quadrivalent Inactivated Influenza Vaccine (HD-IIV4)
Sponsors
Leads: Kaiser Permanente
Collaborators: Seqirus